Published • loading... • Updated
PreludeDx Nears $40M with New Breast Cancer Test - Orange County Business Journal
Summary by ocbj.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PreludeDx Nears $40M with New Breast Cancer Test - Orange County Business Journal
PreludeDx is on track to generate $40 million in revenue this year as it seeks reimbursement for its next-generation risk assessment test for early-stage breast cancer. In April, the FDA granted breakthrough device designation for AidaBreast, the Laguna Hills-based firm’s new test designed to assess a woman’s 10-year breast cancer recurrence risk and predict whether radiation therapy is likely to improve her outcome. The test is designed to help…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
